Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Unknown 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3

Conditions

Nasopharyngeal Carcinoma 12Esophageal Neoplasms 10Esophageal Squamous Cell Carcinoma 8Uterine Cervical Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Carcinoma, Squamous Cell 3Carcinoma, Non-Small-Cell Lung 3Recurrence 2Stomach Neoplasms 1Small Cell Lung Carcinoma 1Resectable Lung Non-Small Cell Carcinoma 1Ovarian Neoplasms 1Neoplasms 1Lymphoma 1Immunotherapy Esophagus Cancer 1Hypopharyngeal Neoplasms 1Hepatic Artery Infusion 1Head and Neck Neoplasms 1Central Nervous System Neoplasms 1Advanced Solid Tumor 1Advanced Non-squamous Non-Small-Cell Lung Cancer 1

Interventions

Cisplatin 281pembrolizumab 234Radiotherapy 171Cetuximab 169Carboplatin 123Docetaxel 110Paclitaxel 96Fluorouracil 95Nivolumab 88Radiotherapy, Intensity-Modulated 80Magnetic Resonance Spectroscopy 39durvalumab 36Radiation 33Surgical Procedures, Operative 32Drug Therapy 32Biopsy 28Radiosurgery 25Erlotinib Hydrochloride 25Albumin-Bound Paclitaxel 24130-nm albumin-bound paclitaxel 24Taxes 23Specimen Handling 22Platinum 22Immunohistochemistry 21tislelizumab 201,2-diaminocyclohexaneplatinum II citrate 20Cyclophosphamide 19Chemoradiotherapy 19Capecitabine 19tremelimumab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Squamous Cell Carcinoma of Head and Neck × nedaplatin × Clear all
NCT06170697 2023-12-20

Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Unknown
46 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06102395 2023-10-30

Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC

Beijing Tongren Hospital

Phase 3 Recruiting
272 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05351762 2022-07-05

Nimotuzumab Combined With Neoadjuvant Chemotherapy in the Treatment of Resectable LA HNSCC

Xijing Hospital

Phase 2 Unknown
55 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon âš¡